Background {#Sec1}
==========

The metabolic syndrome characterized by the simultaneous presence of a number of cardiovascular risk factors such as obesity (particularly visceral adiposity), dyslipidemia, hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL), hypertension, insulin resistance, and impaired glucose tolerance \[[@CR1], [@CR2]\]. Over the past two decades, the prevalence of metabolic syndrome has increased worldwide \[[@CR1]\].

Furthermore, metabolic syndrome and obesity are associated with chronic low-grade systemic inflammation, particularly higher in old females \[[@CR3]\]. Also, chronic low-grade inflammation is described as a significant increase in the systemic concentrations of circulating cytokines, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6) \[[@CR4]\]. The increased cytokine concentrations facilitate the intracellular influx of peripheral blood mononuclear cells (PBMC), which include lymphocytes and monocytes, constituting an important component of the immune system. In this sense, a synergistic relationship between low-grade systemic inflammation and oxidative stress has also been postulated. Regarding this, cytokines and immune cells are able to trigger the production of reactive oxygen (ROS) and nitrogen species (RNS) to cope with defense activities \[[@CR5]\].

In contrast, unbalanced cytokine release results in increased ROS production and oxidative stress-related conditions, such as atherosclerosis, stroke, renal and liver disorders, rheumatoid arthritis, auto-immune deficiencies, cancer, and Alzheimer's and Parkinson's diseases \[[@CR4], [@CR5]\]. Therefore, the evidence points to an interaction among low-grade systemic inflammation and ROS overproduction, leading to these oxidative stress- and inflammation-related conditions previously mentioned. It has been recently stated that aerobic exercise training may be considered as the most effective nonpharmacological means for metabolic syndrome treatment \[[@CR6]\]. However, despite several studies that demonstrated the antioxidant and anti-inflammatory effects of aerobic exercise training \[[@CR7]\], other trials do not present inflammatory and oxidative profiles after a moderate-intensity aerobic exercise training in obese women with metabolic syndrome \[[@CR8]\].

Medicinal herbs are used as supplements along with different training methods for improving health status. Curcumin is a bioactive yellow pigment with a polyphenolic structure that is present in turmeric (*Curcuma longa* L.). In recent years, beneficial reports have been published on the effects of curcumin, suggesting that curcumin is efficient and safe in the prevention and treatment of various diseases \[[@CR9]--[@CR11]\]. Curcumin interacts with various molecular targets including cytokines, growth factors, proteins, enzymes, and receptors \[[@CR12]\]. Furthermore, this polyphenol has anti-inflammatory, antioxidant, and anti-tumor effects \[[@CR13]\]. Although curcumin has been investigated in different clinical conditions, clinical trials evaluating its effect in individuals with metabolic syndrome are scarce \[[@CR14]\].

Thus, the purpose of the present study was to investigate the effect of 6-week aerobic exercise training and nano-curcumin supplementation on inflammatory and oxidative stress parameters in old women with metabolic syndrome.

Methods {#Sec2}
=======

Participants {#Sec3}
------------

Forty-four females with metabolic syndrome aged 60--65 participated in this research after giving written informed consent. This research was conducted according to the guidelines laid down in the Declaration of Helsinki and was approved by the ethics committees of Semnan University of Medical Sciences and Health Services (IR.SEMUMS.REC.1396.107). The participants were recruited after an advertisement in the local hospitals. Participants were recruited only if they met the following criteria: female aged 60--65 years with the metabolic syndrome \[[@CR15]\], non-smoking, no known history of cardiovascular disease, body mass index (BMI) \> 30 kg/m^2^, physically inactive (\< 30 min of physical activity or exercise training per day), and a waist circumference \> 88 cm, which is associated with increased cardiovascular risk was defined as the cut-off \[[@CR16], [@CR17]\].

One is said to have the metabolic syndrome if he or she has central adiposity plus two or more of the following four factors \[[@CR6]\]: (1) raised concentration of triglycerides: ≥ 150 mg/dl (1.7 mmol/L) or specific treatment for this lipid abnormality; (2) reduced concentration of HDL cholesterol: \< 40 mg/dl (1.03 mmol/L) in men and \< 50 mg/dl (1.29 mmol/L) in women or specific treatment for this lipid abnormality; (3) raised blood pressure: systolic blood pressure ≥ 130 mmHg or diastolic blood pressure ≥ 85 mmHg or treatment of previously diagnosed hypertension; and (4) raised fasting plasma glucose concentration ≥ 100 mg/dl (5.6 mmol/l) or previously diagnosed type 2 diabetes \[[@CR18]\].

All subjects completed a questionnaire on physical activity, exercise, dietary intake, lifestyle, and health history prior to the study. The results of the questionnaire showed that the subjects were homogeneous in terms of these factors.

Metabolic syndrome definition {#Sec4}
-----------------------------

Metabolic syndrome was defined according to the criteria of the NCEP/ATP III to include individuals with any three or more of the following five components: (1) abdominal obesity (waist circumference \> 102 cm for men or \> 88 cm for women); (2) high TG ≥ 1.7 mmol/L (150 mg/dl); (3) low HDL-C: Men \< 0.9 mmol/L (\< 40 mg/dl) or women \< 1.0 mmol/L (\< 50 mg/dl); (4) high blood pressure (systolic BP ≥ 130 mm Hg or diastolic BP ≥ 85 mm Hg or treatment of hypertension), and high FBG ≥ 6.1 mmol/L \[[@CR17]\].

Main trials {#Sec5}
-----------

Adopting a double-blind, placebo-controlled, and semi-experimental design, subjects were assigned to four equal groups: (1) placebo (control), aerobic exercise training (E), (2) nano-curcumin supplementation (NC), and (3) combined aerobic exercise training and nano-curcumin supplementation (ENC).

All subjects eligible to participate in the study attended a familiarization session where they were provided with information regarding the study design, testing, and supplementation protocols. None of the subjects had ingested nano-curcumin, or any other dietary supplements before initiation of the study.

The curcumin capsule was provided by the Theravalues Corporation (Tokyo, Japan). The curcumin capsule in the present study consisted of 10% nano-curcumin, 2% curcuminoids, 3.2% gum ghatti, 0.32% citric acid, 54.21% dextrin, and 30% maltose.

The participants were randomly assigned to either the nano-curcumin supplement (80 mg per day) or placebo (80 mg per day maltodextrin) conditions. Both treatments were effervescent capsules, pre-packaged to be identical in appearance, size, and taste. Each group consumed one capsule per day for 6 weeks. During the treatment, subjects orally received 80 mg of nano-curcumin or the same capsules of placebo either 1.5 h before exercise sessions or immediately after breakfast.

Each subject walked or ran at 65--75% heart rate reserve (HRR) on a treadmill for 3 × 12--17 min. Over the 6-week treatment, each week, 1 min was added to each set, beginning with 12 min, so that the duration of each training set at the sixth week was 17 min. Each session consisted of three sets of consecutive sessions with a 5-min rest interval between the sets. Heart Rate was monitored during the test using heart rate monitoring devices (Polar M400; Finland).

Measurement of biochemical parameters {#Sec6}
-------------------------------------

Fasting venous blood samples were taken from the antecubital vein 24 h before and after exercise and supplementation protocols. The samples were taken twice, once at the beginning session and once again at the last session. For measuring serum blood markers, the samples were allowed to clot for 30 min at room temperature and then centrifuged at 3000 rpm for 10 min at 4 ℃. Obtained serums were dispensed into micro tubes and stored at − 80 ℃ until the measurement of blood parameters. For measuring plasma blood markers, blood samples collected into tubes containing ethylene diamine tetra acetic acid (EDTA) were immediately centrifuged and stored at − 80 ℃ until the assay.

Plasma concentrations of interleukin-6 (IL-6), interleukin-10 (IL-10) and brain-derived neurotrophic factor (BDNF) were measured using eBioscience (Vienna, Austria) and Adipo Bioscience (USA) ELISA assay kits, respectively. The ferric reducing ability of plasma (FRAP) was used as a measure of total antioxidant capacity (TAC). Malondialdehyde (MDA) as the end-product of lipid peroxidation was evaluated in the blood and tissue samples as described by the Esterbauer and Cheeseman method. Accordingly, MDA reacts with thiobarbituric acid (Sigma-Aldrich; St. Louis, Missouri, United States), and the pink pigment was produced, which has a maximum absorption at 532 nm. Changes in plasma volume during the acute bout of exercise were calculated using the method outlined by Dill and Costill \[[@CR19], [@CR20]\].

Statistical analysis {#Sec7}
--------------------

Data were presented as mean ± SD. The Kolmogorov--Smirnov test was used to check for normality of distribution of all blood parameters. The distribution of these parameters did not differ significantly from normal. Using paired-samples t-test, the data were analyzed for the main effects of trial and time as well as the interaction of time × trial. Statistical significance was set at P \< 0.05. Data analysis was performed using SPSS version18 software.

Results {#Sec8}
=======

The physical qualities of subjects were measured twice: at the first and the last sessions. The measures are as follows in the last session: expressed as mean ± standard deviation \[SD\]: age, 62.3 ± 1.23 years; height, 164 ± 7 cm; body weight, 81.2 ± 2.4 kg; and body mass index (BMI), 29.5 ± 1.2 kg/m^2^.

The results of a within-group comparison of metabolic syndrome, weight, fat percentage, BMI, IL-6, IL-10, BDNF are listed in Tables ([1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). The blood pressure, triglyceride, waist circumference, BMI, weight, body fat percentage, and IL-6 concentration were lower in the aerobic training group than in the placebo group after the intervention (P \< 0.01) Tables ([1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}). Also, the results of the present study suggested that nano-curcumin supplementation significantly decreases serum concentrations of TNF-a, IL-6, MDA, and hs-CRP in subjects with metabolic syndrome. In addition, the results of the present study suggested that nano-curcumin supplementation significantly increases serum concentrations of BDNF, IL-10, and TAC in subjects with metabolic syndrome.Table 1Biochemical variables in nano-Curcumin, aerobic training, combined and Placebo groupsVariableGroupsENC*P*E*P*NC*P*C*P*SBP (mmHg) Pre145.4 ± 9.10.001145.2 ± 15.20.001146.9 ± 11.70.001152 ± 14.690.68 Post120 ± 2.61137.7 ± 7.89132.1 ± 10.26152.7 ± 11.47Waist circumference (cm) Pre103.5 ± 6.840.001105 ± 10.80.001102.4 ± 5.690.32104.8 ± 6.970.9 Post98.75 ± 5.86101.08 ± 5.61103.9 ± 6.87104.2 ± 6.47Glucose (mg/dl) Pre172.5 ± 52.70.001170.2 ± 50.50.001178.6 ± 52.80.001183.1 ± 52.80.75 Post108.83 ± 7.06125.9 ± 27.2111.4 ± 9.59182.1 ± 51.34Triglyceride (mg/dl) Pre232.1 ± 62.70.001223.08 ± 64.50.001215.6 ± 50.40.001225.8 ± 69.20.01 Post161.6 ± 39.9197.7 ± 69.2164.6 ± 24.13180.3 ± 55.2HDL (mg/dl) Pre46.66 ± 7.030.00147.25 ± 5.220.00146.7 ± 3.740.00145.6 ± 5.180.08 Post56.91 ± 7.2653.33 ± 4.3552.6 ± 3.244.7 ± 2.79BMI (kg m^−2^) Pre31.24 ± 3.120.00132.22 ± 2.460.00129.54 ± 2.670.0229.02 ± 1.560.11 Post29.91 ± 3.2531.27 ± 2.3929.66 ± 2.629.11 ± 1.51Weight (kg) Pre77.01 ± 3.650.00177.67 ± 2.950.00176.12 ± 5.510.0374.72 ± 5.320.11 Post73.69 ± 4.1175.38 ± 2.9876.43 ± 5.4674.97 ± 4.32Body fat (%) Pre37.96 ± 3.070.00137.2 ± 3.670.00136.7 ± 4.110.0137.4 ± 4.450.001 Post33.5 ± 2.9635.08 ± 4.0135.6 ± 4.1438.01 ± 4.16*BMI* body mass index, *SBP* systolic blood pressure, *IL-6* interleukin-6, *IL-10* interleukin-10, *BDNF* brain-derived neurotrophic factor, *TAC* total antioxidant capacity, *MDA* malondialdehyde, *CRP* C-reactive proteinTable 2Biochemical variables in nano-Curcumin, aerobic training, combined and Placebo groupsVariableGroupsENC*P*E*P*NC*P*C*P*IL-6 (pg/mL) Pre18.88 ± 2.390.00118.05 ± 2.340.00119 ± 2.580.00119.16 ± 2.680.47 Post13.65 ± 2.414.92 ± 2.3815.68 ± 2.3818.68 ± 2.71IL-10 (pg/mL) Pre7.74 ± 1.170.0017.59 ± 1.160.0018.1 ± 1.360.0018.23 ± 1.310.09 Post10.97 ± 0.386.69 ± 0.7110.72 ± 1.417.85 ± 1.15BDNF (pg/mL) Pre115.33 ± 15.310.001113.16 ± 14.60.001110.6 ± 15.490.001107 ± 17.610.26 Post273.5 ± 15.86172.08 ± 9.6198.5 ± 15.7105.2 ± 16.14TAC (mmol/L) Pre0.582 ± 0.320.0010.504 ± 0.480.0010.541 ± 0.210.0010.518 ± 0.410.58 Post1.22 ± 0.621.28 ± 0.681.31 ± 0.780.521 ± 0.8MDA (nmol/dL) Pre2.68 ± 0.710.0012.74 ± 0.780.0012.59 ± 0.820.0012.79 ± 0.610.61 Post1.47 ± 0.621.42 ± 0.681.32 ± 0.782.81 ± 0.8CRP (pg/mL) Pre2.31 ± 0.720.0012.24 ± 0.670.0012.26 ± 0.580.0012.29 ± 0.710.74 Post1.21 ± 0.841.34 ± 0.611.18 ± 0.672.31 ± 0.79*BMI* body mass index, *SBP* systolic blood pressure, *IL-6* interleukin-6, *IL-10* interleukin-10, *BDNF* brain-derived neurotrophic factor, *TAC* total antioxidant capacity, *MDA* malondialdehyde, *CRP* C-reactive protein

Discussion {#Sec9}
==========

The moderate-intensity aerobic exercise training induced total body fat percentage decrease in women with metabolic syndrome. Changes in total body fat mass are likely connected with the decreased inflammatory cytokines levels \[[@CR16], [@CR21]\]. In addition, the adipose tissue is considered not only a fat reservoir but also an endocrine tissue associated with insulin sensitivity, endocrine systems, and inflammation \[[@CR16]\]. In fact, moderate-intensity aerobic exercise training increases energy expenditure and lipolysis in subcutaneous and intramuscular fat stores accumulated in metabolic syndrome patients.

Elevated white adipose tissue, hyperglycemia, endothelial ROS production, and inadequate antioxidant defenses are connected to oxidative stress in obesity \[[@CR22]\]. In the current study, the moderate-intensity aerobic exercise training induced reduction on oxidative damage (MDA) indicator with a concomitant increase in antioxidant status (TAC) in metabolic syndrome women, indicating oxidative balance. The long-term exercise-induced adaptations of oxidative stress are similar to the general principles of exercise training. This suggests that the chronic exposure to pro-oxidant agents such as bouts of moderate aerobic exercises results in the upregulation of antioxidant defenses, providing a balance between the ROS-induced damage and the antioxidant systems \[[@CR23]\].

This study found that a 6-week moderate-intensity aerobic exercise training reduced IL-6 and CRP serum levels, while IL-10 and BDNF increased. Some mechanisms have been proposed to explain how exercise training may reduce chronic low-grade inflammation in MS. It is known that in addition to the adipose tissue, the working skeletal muscle is a potential source of cytokines. The IL-6 produced by myocytes through AMP-activated protein kinase (AMPK) activation at sufficient AT intensities presents anti-inflammatory effects as opposed to IL-6 secreted by adipose tissue, promoting the release of IL-10 and interleukin-1 receptor antagonist (IL-1RA), with a concomitant inhibition of TNF-α production during the effort and some hours after the exercise sessions. Another possible mechanism is the reduced expression of the toll-like receptors and nuclear transcription factor κB (NFκB) on monocytes and macrophages, probably linked to hormonal and heat shock protein levels, increased lipolysis, and reduced number of monocytes reported in some studies. Moreover, recent evidence shows that exercise training may increase angiogenesis and blood supply, thereby reducing hypoxia and the associated inflammation in adipose tissue \[[@CR21]\].

Previous studies concerning serum or plasma cytokine levels and their concentrations have evaluated the acute effects of exercise \[[@CR24]\]. Based on the findings reported in previous as well as the present study, it could be hypothesized that major weight loss connected to exercise training is necessary to modulate inflammatory indicators levels \[[@CR25], [@CR26]\]. Also, we found a significant reduction of IL-6 and CRP in women with metabolic syndrome. In this regard, some of the previous studies have shown significant reductions in C-reactive protein concentration which is another important indicator of systemic inflammation, following nano-curcumin intake and supplementation \[[@CR14]\].

Several studies have reported positive effects of nano-curcumin supplementation in the prevention and treatment of obesity, atherosclerosis, diabetes, and metabolic syndrome \[[@CR27]\]. Nano-curcumin is involved in several mechanisms inhibiting inflammatory cytokines production from adipose tissue. Research shows that nano-curcumin can suppress vital transcription factors such as nuclear factor kappa B, resulting in inhibition of inflammatory cytokines gene expression \[[@CR28]\]. Another possible mechanism is suppressing inflammatory cytokines production through down-regulation of intracellular signaling protein kinases by nano-curcumin. Moreover, nano-curcumin reduces macrophage accumulation in adipose tissue by suppressing the expression of inflammatory cytokines and subsequent inhibition of obesity-induced inflammatory response \[[@CR29]\]. Aside from direct inhibitory effects on cytokine production and release, mitigation of several components of metabolic syndromes, such as obesity, insulin resistance, dyslipidemia, hyperglycemia, and hypertension, may be responsible for the decreased levels of pro-inflammatory cytokines following nano-curcumin supplementation.

Conclusions {#Sec10}
===========

In conclusion, training with or without the nano-curcumin supplementation and the supplementation alone could improve inflammation, BDNF concentration, and stress oxidative indices, as well as the glycemic level, in the elderly females with metabolic syndrome. Besides, nano-curcumin supplementation has positive effects for the improvement of stress oxidative index. Moreover, aerobic exercises with or without the nano-curcumin supplementation and the supplementation alone could improve total antioxidant capacity and hsCRP. Overall, performing aerobic exercises with nano-curcumin supplementation is suggested as a helpful supplementary treatment for decreasing the inflammation in patients with metabolic syndrome. Needless to say, more studies are needed in this area to determine the best dose of supplementation and exercise intensity and volume.
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